Skip to main content
OpenTrials
Completed

NCT Number: NCT04469686

Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

A randomized, multi-center, double-blind, three arm placebo-controlled study in male and non-pregnant, non-lactating female subjects aged 18 years to examine the safety and efficacy of two dosing regimens of hydrocortisone acetate 90 mg suppository administered with the Sephure suppository applicator for the treatment of ulcerative colitis of the rectum.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Hospital Sveti Panteleimon, Plovdiv, Bulgaria

Loading trial locations.

About this study

Hydrocortisone acetate 90 mg or placebo will be administered as a rectal suppository with a Sephure suppository applicator. Two arms of the study will receive different dosage regimens of hydrocortisone acetate, and the third arm will receive placebo. All subjects will administer the study drug twice a day; once in the morning and once in the evening for 28 days.

The study population will consist of male and non pregnant, non lactating females aged 18 years and older with a confirmed diagnosis of active ulcerative colitis of the rectum.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or non pregnant, non lactating females aged 18 years and older.
  • Able to provide informed consent.
  • Subjects with a confirmed diagnosis of active UC of the rectum, extending no more than 15 centimeters (cm) (5.9 inches) proximal to the anal verge as assessed by colonoscopy performed at Visit 2. Note: Subjects may have a history of more extensive UC (e.g., pancolitis), but have active disease only in the rectum at the time of enrollment.
  • Modified Mayo sub score for stool frequency of 1-3.
  • Modified Mayo sub score for rectal bleeding of 0-2.
  • Modified Mayo endoscopic sub score of 2-3.
  • Total Modified Mayo Score (without physician global assessment) of 4-8.

Exclusion criteria

  • History or current diagnosis of bacterial or other infectious colitis, radiation enteritis and radiation proctitis, Crohn's disease, collagenous colitis and indeterminate colitis.
  • Prior gastrointestinal surgery except appendectomy, cholecystectomy, and hernia.
  • Concomitant active lower gastrointestinal disease (except Irritable Bowel Syndrome) or distortion of intestinal anatomy.
  • Bleeding hemorrhoids at the time of enrollment.
  • Acute diverticulitis at the time of enrollment.
  • Acute or chronic pancreatitis at the time of enrollment.
  • Unmanaged celiac disease at the time of enrollment.
  • Positive stool test for enteric pathogens, Clostridium difficile, or presence of ova and parasites.
  • Taking a prohibited medication.

Treatment and study plan

Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator

Combination Product

Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator

Other names: Twice Daily - Active

Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator

Combination Product

Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator

Other names: Once Daily - Active

Twice daily placebo suppository administered with Sephure applicator

Combination Product

Twice daily placebo suppository administered with Sephure applicator

Other names: Twice Daily - Placebo

Primary outcomes

  1. Clinical Remission

    Time frame: 29 days

    The primary efficacy endpoint was specified as the between-treatment group (HCA Suppository 90 mg bid versus placebo and HCA Suppository 90 mg qd versus placebo) difference in the proportion of subjects with clinical remission at the End of Treatment visit (Day 29). Clinical remission was defined as a Modified Mayo Total Score of 0 to 2, with stool frequency subscore of 0 or 1 (minimum 1 point decrease from baseline), rectal bleeding subscore of 0, and endoscopic subscore of 0 or 1.

Secondary outcomes

  1. Reduction of Stool Frequency

    Time frame: 29 days

    Reduction of stool frequency measured using Mayo Scoring sub score of stool frequency to assess the change in stool frequency from Baseline (Day 1) to End of Treatment (Day 29) and from Baseline (Day 1) to Follow-up (Day 15).

  2. Rectal Bleeding

    Time frame: 29 days

    Rectal Bleeding measured using Mayo Scoring sub-score of rectal bleeding equal to assess the change in rectal bleeding in active treatment groups vs. placebo group from Baseline (Day 1) to End of Treatment (Day 29) and from Baseline (Day 1) to Follow-up (Day 15).

Sponsors and collaborators

Lead sponsor

Cristcot HCA LLC

Industry

Registry information

Official study title

3-Arm Randomized Placebo Controlled Double Blind Phase 3 Study to Evaluate Safety and Efficacy of Once-Daily and Twice-Daily Hydrocortisone Acetate 90 mg Suppository Administered With a Sephure Suppository Applicator in Subjects With Ulcerative Colitis of the Rectum

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Jul 14, 2020
Registry last updated
Aug 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.